Drug Type Small molecule drug |
Synonyms GL-2504 |
Target |
Action inhibitors |
Mechanism Dopamine reuptake inhibitors, NET inhibitors(Norepinephrine transporter inhibitors), Serotonin reuptake inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (01 Dec 2011), |
Regulation- |
Molecular FormulaC21H30ClNO4 |
InChIKeyZHMPDWYRECUDOQ-BTJKTKAUSA-N |
CAS Registry1258859-73-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anorexia Nervosa | South Korea | 01 Dec 2011 |
Phase 4 | 14 | Placebo+Sibutramine (Sibutramine) | kfsirdpccu(blvmddzucc) = zjnwrizgoo amrlaliqbz (gsdzdqitlv, 655) View more | - | 31 Jul 2017 | ||
Placebo+Sibutramine (Placebo) | kfsirdpccu(blvmddzucc) = naienragxi amrlaliqbz (gsdzdqitlv, 774) View more | ||||||
Phase 4 | 104 | (Sibutramine) | iwllhcabac = ndfwlcswsx yoxpaqvzkr (pzbmlhnxzk, wogdjvarsx - mpwpkkswvs) View more | - | 12 Dec 2014 | ||
Placebo (Placebo) | iwllhcabac = jlkapzxuno yoxpaqvzkr (pzbmlhnxzk, yedinywujc - txydlfdays) View more |